US Patent

US8129374 — Method of using imidazolothiazole compounds for the treatment of disease

Method of Use · Assigned to Ambit Bioscience Corp · Expires 2027-03-16 · 1y remaining

Vulnerability score 88/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a method of using imidazolothiazole compounds, including quizartinib dihydrochloride, to treat diseases or disorders mediated by receptor kinases.

USPTO Abstract

Compounds, compositions and methods are provided for modulating the activity of receptor kinases and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by receptor kinases.

Drugs covered by this patent

quizartinib-dihydrochloride (QUIZARTINIB DIHYDROCHLORIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3661`	—	quizartinib-dihydrochloride
`U-3661`	—	quizartinib-dihydrochloride

Patent Metadata

Patent number: US8129374
Jurisdiction: US
Classification: Method of Use
Expires: 2027-03-16
Drug substance claim: No
Drug product claim: No
Assignee: Ambit Bioscience Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.